Oncotelic Therapeutics enters consulting agreements with Jefferson Capital and Valor Nation for strategic services

Oncotelic Therapeutics, Inc.

Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.
Jefferson receives $20,000/month cash and up to 20,320,930 restricted stock awards tied to milestones: market cap >$100M, $10M equity increase, uplisting.
Valor receives 4,064,586 shares of common stock immediately upon signing.
Jefferson's RSAs vest in thirds per milestone; unvested shares forfeited if milestones not achieved.
Shares issued under Section 4(a)(2) exemption from Securities Act registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.